Treatment modalities and risk of adverse events associated with biologic therapy: A 10‐year observational review of the Australasian Psoriasis Registry-Reference-Cited by-同舟云学术

Treatment modalities and risk of adverse events associated with biologic therapy: A 10‐year observational review of the Australasian Psoriasis Registry

Published:2020-09-04 Issue:1 Volume:62 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Australas J Dermatol

Author:

Doolan Brent J¹²³^ORCID,Koye Digsu⁴,Ling Joanna⁴,Cains Geoffrey D⁵⁶,Baker Christopher²⁷,Foley Peter²⁷,Dolianitis Con¹⁸

Affiliation:

1. Department of Dermatology The Royal Melbourne Hospital Melbourne VictoriaAustralia

2. Skin Health Institute Carlton VictoriaAustralia

3. The Skin Hospital Sydney New South WalesAustralia

4. The Melbourne EpiCentre University of Melbourne and Melbourne Health Melbourne VictoriaAustralia

5. Department of Dermatology Liverpool Hospital Sydney New South WalesAustralia

6. School of Medicine University of New South Wales Sydney New South WalesAustralia

7. Department of Dermatology and Medicine St Vincent’s Hospital, MelbourneThe University of Melbourne Fitzroy VictoriaAustralia

8. Department of Medicine The University of Melbourne Melbourne Victoria Australia

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.13450

Reference28 articles.

1. A systematic review of worldwide epidemiology of psoriasis

2. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology

3. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

4. Biologic Therapy in Psoriasis: Safety Profile

5. Safety of biologics in psoriasis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and patient‐reported outcomes from the first 4 years of a Psoriasis Biologics Registry in Singapore;Experimental Dermatology;2023-08-16

2. Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients;Australasian Journal of Dermatology;2023-07-28

3. Effect of Chinese herbal medicine injections for treatment of psoriasis vulgaris: a systematic review and meta-analysis;Frontiers in Pharmacology;2023-07-03

4. Long-Term Registry Data for Psoriasis Biologics;Updates in Clinical Dermatology;2022

5. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis;Chinese Medical Journal;2020-11-09